Provider Respiratory Inservice

Similar documents
Nancy Davis, RRT, AE-C

MANAGING ASTHMA. Nancy Davis, RRT, AE-C

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018

COPD: Current Medical Therapy

Asthma. Definition. Symptoms

Asthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options

STRIVERDI RESPIMAT (olodaterol hcl) aerosol

Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Asthma COPD Overlap (ACO)

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Allergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma

Effective Date: 4/27/2016 Version: 1.0 Approval By: CCC Clinical Delivery Steering Planned Review Date: 4/27/2017

Respiratory Health. Asthma and COPD

Presented by UIC College of Nursing

Chronic Obstructive Pulmonary Disease 1/18/2018

Asthma By Mayo Clinic staff

Improving Outcomes in COPD

COPD. Stan Kellar, MD. Physiology 11/4/2014. Chief of Clinical Affairs, BH NLR Pulmonary Medicine Sleep Medicine

FASENRA (benralizumab)

Chronic Obstructive Pulmonary Disease

COPD. Diseases and Conditions

COPD. Definitionn. make. when (bronchioles) in. the lungs. Wheezing Chest tightness. your lungs. greenish. Lack of energy

ASTHMA IN THE PEDIATRIC POPULATION

Drug Class Monograph

Learning Objective. Asthma. Discuss the pathophysiology, clinical presentation, diagnosis, and treatment of Asthma 2/22/2017

Women Beware-The Threat of COPD

Medications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources

Medications Affecting The Respiratory System

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.

COPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute

Asthma ASTHMA. Current Strategies for Asthma and COPD

Chronic Obstructive Pulmonary Disease

People with asthma who smoke. The combination of asthma, a chronic airway disease, and smoking increases the risk of COPD even more.

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline

Pediatric Asthma Management

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

SCREENING AND PREVENTION

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

COPD: A Renewed Focus. Disclosures

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

Chronic obstructive pulmonary disease

A Visual Approach to Simplifying Respiratory Drug Regimens

Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD

MANAGEMENT OF ASTHMA SPRING Presented by:

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

Assessing Severity. Management of Stable COPD. General Approach. Short Acting Bronchodilators. Staging System (GOLD)

Inhaled Corticosteroids Drug Class Prior Authorization Protocol

Chronic Obstructive Pulmonary Disease

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

Foundations of Pharmacology

HEALTH SERVICES POLICY & PROCEDURE MANUAL

Women Beware The Threat of COPD

RESPIRATORY CARE IN GENERAL PRACTICE

Three s Company - The role of triple therapy in chronic obstructive pulmonary

MDI Bonanza. Dwayne Griffin, DO

UPMC HEALTH PLAN COPD CLINICAL PRACTICE GUIDELINE

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens

Chronic Obstructive Pulmonary Disease (COPD) October Highlights:

Abbreviated Class Review: Chronic Obstructive Pulmonary Disease (COPD)

Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives.

Guideline for the Diagnosis and Management of COPD

COPD COPD. Update on COPD and Asthma

10/18/2012. Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C

Allwin Mercer Dr Andrew Zurek

What is New in COPD: Times Are Changing! Meredith Chiasson, MD, FRCPC April 6, 2018

COPD. Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS

reslizumab (Cinqair )

Alberta Childhood Asthma Pathway for Primary Care

Inhaled Corticosteroids Drug Class Prior Authorization Protocol

benralizumab (Fasenra )

ASTHMA BEST PRACTICES FOR SCHOOL NURSES. School Nurses November 2015

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes

Asthma in the Athlete

Chronic Obstructive Pulmonary Disease Guidelines and updates

2/12/2015. ASTHMA & COPD The Yin &Yang. Asthma General Information. Asthma General Information

Roflumilast (Daxas) for chronic obstructive pulmonary disease

Individualizing and Optimizing Asthma Care. CFW 2018 Friday, April 13, 9:45 11:15 am Renaissance Austin Hotel in Austin, Texas

COPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust

Improving the Management of Asthma to Improve Patient Adherence and Outcomes

Chronic Obstructive Pulmonary Disease

Asthma for Primary Care: Assessment, Control, and Long-Term Management

Asthma 2015: Establishing and Maintaining Control

COPD/Asthma. Prudence Twigg, AGNP

(pedi) Patient Name: date of birth:

Key features and changes to these four components of asthma care include:

Asthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)

Nucala (mepolizumab injection for subcutaneous use)

Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ

Take My Breath Away: COPD Update. Jason Henderson D.O. Warren Clinic Pulmonary & Critical Care

Asthma COPD Update 2018

Asthma in Pediatric Patients. DanThuy Dao, D.O., FAAP. Disclosures. None

PFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA

Transcription:

Provider Respiratory Inservice

2 Welcome

Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines for diagnosis, evaluation, and management of adult with COPD Coding BC/BS services available to assist your practices 3

What is Asthma? Obstructive lung disease with characteristics of: Airway obstruction; reversible in most patients Chronic airway inflammation (eosinophils) Increased airway responsiveness Onset of symptoms can occur at any age 4

Asthma 34 million people in the U.S. currently diagnosed with asthma 7.1 million children are diagnosed with asthma 1.3 million visits to hospital outpatient departments with asthma as a primary diagnosis Asthma costs exceed $30 billion/year Asthma in the U.S. is growing every year 5 U.S Department of Health and Human Resources Center for CDC: 12/2012

What is COPD? A common, preventable, and treatable disease: Characterized by persistent airflow limitation Usually progressive Associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients. 6

COPD 16 million U.S. adults have been diagnosed with COPD 15 million or more U.S. adults have COPD that have not been diagnosed 4 th leading cause of death in the U.S. Annual direct & indirect COPD Medical Costs $42.6 billion 7 U.S Department of Health and Human Resources Center for CDC: 2007

Differential Diagnosis Asthma SUGGESTIVE FEATURES * Onset early in life (often childhood). * Symptoms vary from day to day. * Symptoms at night/early morning. * Allergy, rhinitis, and/or eczema also present. * Family history of asthma. COPD SUGGESTIVE FEATURES * Onset in mid-life. * Symptoms slowly progressive. * Long smoking history. * Dyspnea during exercise. * Largely irreversible airflow limitation. * Largely reversible airflow limitation. 8

Asthma vs. COPD Spirometry is required pre- and postbronchodilator to help differentiate between Asthma and COPD Asthma = Reversibility COPD = No/partial reversibility Chest Xray to order or not? Vaccinate for flu and pneumonia 9

Case Study 45 year old female presents to the office with complaints of shortness of breath and wheezing. She has a history of asthma. 10

History Questions to ask Symptoms (wheezing, dyspnea, cough) Timing and Frequency Triggers Work environment: dust, fumes, chemicals Home environment: heating, mold, pets, dust, roaches, cigarette/cigar smoke Exercise Upper Respiratory Infections 11 Medications inhalers, steroids and other medications Smoking history Family history

Findings Smoker 1 ppd X 10 years, quit age 30 SOB and wheezing daily Uses albuterol inhaler 1x per day Wakes at least 1 night per week with a cough Becomes SOB with exercise Works at Chevy plant Monday Friday 2 courses of oral systemic corticosteroids last 6 months 12

13 Spirometry

14 Asthma Spirometry Results

Asthma Spirometry Results Pre Post Bronchodilator Bronchodilator Predicted Actual Predicted % Actual Predicted % % Change FEV1 (L) 3.11 2.21 71 2.49 80 13% FVC (L) 3.88 3.33 86 3.53 91 6% FEV1/FVC % 83 66 71 15

Guidelines 16 http://www.nhlbi.nih.gov/guidelines/asthma/asthma_qrg.pdf

Classifying Asthma Severity According to EPR-3 guidelines, the member is classified as having moderate persistent asthma Diagnosis = moderate persistent asthma Next - therapy 17

18

19 Step approach medications

Asthma Medications Quick-Relief medication: SABA (Short-Acting Beta Agonists) Controller medications: ICS (Inhaled Corticosteroids) LABA (Long-Acting Beta Agonists) LABA/ICS Combinations LEUKOTRIENE MODIFIERS Miscellaneous (theophylline, cromolyn) 20

Next Steps Education: Review Medications Review inhaler technique + compliance at each visit Reducing exposure to triggers Review asthma action plan each follow-up visit Smoking cessation assistance Vaccinate for flu and pneumonia 21

22 Asthma Action Plan

23 Follow-up: 2-6 weeks after initial visit ACT test patient completes Assess level of symptom control with current medication regime Medication compliance and technique Step up or step down, according to signs and symptoms Patient education Referral to pulmonologist or allergist, if needed Review and update Asthma action plan Encourage compliance

Asthma Control Test 4 4 5 4 4 21 24

25 Case study follow-up ACT test review SOB 1X in 3 weeks No nighttime awakening No SOB while exercising Use albuterol inhaler 1X in 3 weeks Repeat spirometry showed FEV1 > 80% predicted Next follow up appointment in 1-6 months Well controlled Consider step down if well controlled for at least 3 months

26 Follow-up

Case Study 45 year old female presents to the office with complaints of shortness of breath and wheezing. 27

History Questions to ask Symptoms (SOB, cough, wheezing, phlegm production, color, amount) Timing and Frequency Smoking history Medications inhalers, steroids, other medications Family history 28

Findings Smoker 2ppd since age 20 Dyspnea and wheezing Uses albuterol inhaler 1x per day Experiences cough and some dyspnea with exercise Productive cough with white sputum Works at Chevy plant Monday Friday Has been treated with 2 courses of Prednisone in the past 6 months 29

Is this COPD? Spirometry MUST be performed! Within 180 days from initial diagnosis Pulse oximetry to do or not? Chest Xray to do or not? 30

31 COPD Spirometry Results

COPD Spirometry Results Pre Post Bronchodilator Bronchodilator Predicted Actual Predicted % Actual Predicted % % Change FEV1 (L) 3.11 1.87 60 1.94 62 4% FVC (L) 3.88 3.1 80 3.15 81 2% FEV1/FVC % 83 60 62 32

COPD Medications SABA (Short-Acting Beta Agonists) ICS (Inhaled Corticosteroids) LABA (Long-Acting Beta Agonists) LABA/ICS Combinations Anticholinergics Miscellaneous (theophylline, roflumilast, combivent) 33

Medications for Asthma & COPD Pharmacy Formulary Type of Medication Commercial/ Child Health Plus/ Healthy New York Medicaid/ Family Health Plus Medicare SABA ProAir HFA ProAir HFA ProAir HFA Proventil HFA Ventolin HFA Xopenex HFA LABA Foradil, Serevent Diskus Serevent Diskus Arcapta, Foradil, Perforomist, Severent Diskus ICS Asmanex, Flovent Diskus/HFA, Pulmicort, QVAR Alvesco, Flovent Diskus HFA, Pulmicort Flexhaler, QVAR Alvesco, Asmanex, Flovent Diskus/HFA, QVAR LABA/ICS combos Advair, Symbicort Advair, Symbicort Advair, Dulera, Symbicort Anticholinergics Spiriva, Atrovent Spiriva, Atrovent Spiriva, Atrovent Miscellaneous Combivent, montelukast, zafirlukast Combivent, montelukast, zafirlukast Combivent, Daliresp, montelukast, zafirlukast 34 * Included medications are tier 1 (generics) and tier 2 (brands) for commercial/hny/chp. *Included medications are covered for Medicaid on generic or brand tier. *Included medications are tier 2 (non-preferred generic) and tier 3 (preferred brand) for Medicare

Next Steps Review medications Review inhaler technique & compliance at each visit Review care plan each follow up visit Smoking cessation assistance Vaccinate for flu and pneumonia 35

Follow up Follow up Q 6 months or sooner if hospitalized or in ED for COPD Review symptoms at each visit Review Medications Spirometry every year 36

Asthma Codes Asthma Codes Identifying Asthma Description ICD-9-CM Diagnosis Extrinisic (allergic) asthma 493.0 Intrinsic (non-allergic) asthma 493.1 Asthma + COPD 493.2 Asthma unspecified 493.9 Status asthmaticus Add "1" as fifth digit to 493.0 or 493.1 or 493.2 or 493.9 Asthma exacerbation Add "2" as fifth digit to 493.0 or 493.1 or 493.2 or 493.9 Exercise induced asthma 493.81 Cough variant asthma 493.82 37

38

COPD Codes COPD Codes Identifying COPD Description ICD-9-CM Diagnosis Chronic bronchitis - simple (catarrhal, "smoker's cough) 491.0 Chronic bronchitis - mucopurulent 491.1 Emphysema 492.8 Chronic bronchitis + emhysema 491.20 COPD with acute exacerbation 491.21 COPD with acute bronchitis 491.22 COPD nonspecific 496 Note: chronic bronchitis involves a persistent cough with sputum production for at least 3 months in at least 2 consecutive years 39

Smoking Cessation Codes Smoking Cessation Description CPT for 3-10 minutes of counseling 99406 for over 10 minutes of counseling 99407 * If a modifier is used on the smoking cessation code, documentation must support both of the criteria for the E&M code and the smoking cessation code. 40

Pulse Oximetry & Spirometry Testing Codes Pulse Oximetry Description CPT Non-invasive ear or pulse oximetry for oxygen saturation; single determination 94760 Multiple determinations 94761 Spirometry Testing Description Spirometry 94010 Spirometry pre and post bronchodilator administration 94060 CPT 41

Flu and Pneumococcal Vaccine Codes Flu Vaccine Codes Description CPT Influenza virus, preservative free, intramuscular administration 3 years of age and older 90656 Influenza virus, intramuscular administration 3 years of age and older 90658 Influenza virus, nasal administration 90660 Adult Pneumococcal Vaccine Description Adult pneumoccoccal vaccine (23-valent polysaccharide) 90732 CPT 42

Administration Codes Admin Codes Description IM administration 1st component through age 18 with counseling CPT 90460 Each additional component through age 18 with counseling 90461 Immunization administration all ages without counseling 90471 Immunization administration-each additional all ages without counseling Immunization oral/nasal administration all ages without counseling Immunization oral/nasal administration-additional all ages without counseling 90472 90473 90474 43

How we can help you One on one health coaching with a registered nurse available to assist our BCBS members Educate about disease process Medication management Address gaps in care Coordinate services Reinforce treatment plan 44

How we can help you We also have a team of social workers, dieticians and outreach workers Community classes: Smoking cessation Nutrition Weight management Exercise programs Stress management www.bcbswny.com 45

How to access DM/CM services Fax referral form to 716-887-7913 Phone call 1-877-878-8785, option 2 Member self referral online at www.bcbswny.com DM = Disease mangement CM = Case management 46

47 Questions

Thank You!